MG is a paid consultant for Aquestive, related to epinephrine drug development; has received personal fees for medical advisory board work related to food allergy, eczema, and eosinophilic oesophagitis management and treatment strategies from DBV Technologies, Sanofi/Regeneron, Genentech, Nutricia, Novartis, Acquestive, Allergy Therapeutics, Pfizer, US World Meds, Allergenis, ALK-Abello, AstraZeneca, Aravax, and Prota; is the senior associate editor for the Annals of Allergy, Asthma, and Immunology, for which he receives a stipend; has received one-time honorarium for continuing medical education lectures from ImSci, MedLearningGroup, and multiple state and local allergy societies; is an unpaid member of the scientific advisory council for the National Peanut Board related to peanut allergy education, the Brighton Collaboration Criteria Vaccine Anaphylaxis 2.0 working group for adverse reactions to vaccines, and the Joint Taskforce on Allergy Practice Parameters, which creates conjoint practice guidelines for the American Academy of Allergy, Asthma and Immunology and the American College of Allergy, Asthma and Immunology. EMA is a part-time employee of the Public Health Agency of Canada (PHAC), but the views expressed are her own and not those of PHAC. MS is an associate editor for the Annals of Allergy, Asthma, and Immunology, for which he receives a stipend; is an unpaid member and co-chair of the Joint Taskforce on Allergy Practice Parameters, which creates conjoint practice guidelines for the American Academy of Allergy, Asthma and Immunology and the American College of Allergy, Asthma and Immunology; serves on the editorial boards of the Journal of Allergy and Clinical Immunology In Practice and the Journal of Food Allergy; and has a family member who is chief executive officer of Altrix Medical (not involved in allergy treatments or related products).